Cancer BiologybioRxiv
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer
P. D. Dunne, H. G. Coleman, P. Bankhead…·M. Lawler
The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.
DOI 10.18632/oncotarget.24481